GlassScriptPhysician profile
Marcie Nicks
NPI 1215388871
$2,469.03
in general payments reported to CMS, 2019-2025
28 companies · $564 in 2025
The $564 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $416 · 2022: $517 · 2023: $409 · 2024: $563 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,535.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $467.24 | 2021-2024 | Veozah, Myrbetriq |
| Medtronic, INC. | $357.25 | 2021-2025 | Interstim, Truclear |
| Sumitomo Pharma America, INC. | $299.05 | 2023-2025 | Gemtesa, Myfembree, Orgovyx |
| Abbvie INC. | $260.42 | 2021-2025 | |
| Coloplast Corp | $132.12 | 2021-2025 | |
| Boston Scientific Corporation | $89.73 | 2022-2025 | Varithena Administration Pack |
| Axonics, INC. | $86.73 | 2021-2023 | Bulkamid |
| Urovant Sciences INC | $82.57 | 2022 | |
| Hologic Sales and Service, LLC | $74.42 | 2024-2025 | Myosure Tissue Removal Device, Fluent Fluid Management System, Novasure |
| Channel Medsystems, INC. | $73.55 | 2022 | |
| Mayne Pharma Commercial LLC | $60.25 | 2022-2023 | |
| Aspira Women'S Health INC | $59.94 | 2022 | |
| Becton, Dickinson and Company | $43.55 | 2025 | Arista |
| Ferring Pharmaceuticals INC. | $42.17 | 2025 | Adstiladrin |
| Olympus America INC. | $37.86 | 2021-2024 | Olympus |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $35.41 | 2022 | |
| Pfizer INC. | $33.26 | 2021 | |
| Urogen Pharma, INC. | $31.74 | 2025 | |
| Dendreon Pharmaceuticals LLC | $30.40 | 2025 | Provenge |
| Janssen Biotech, INC. | $28.90 | 2025 | Erleada |
| Agile Therapeutics, INC. | $21.95 | 2023 | Twirla |
| Endo USA, INC. | $21.63 | 2025 | Xiaflex |
| Novartis Pharmaceuticals Corporation | $18.97 | 2025 | |
| Conmed Corporation | $18.82 | 2025 | Airseal |
| Smith+Nephew, INC. | $18.53 | 2024 | Stravix |
| Exeltis, USA INC. | $14.74 | 2022 | |
| Baxter Healthcare | $14.44 | 2024 | Perclot |
| Shield Therapeutics INC | $13.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcie Nicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.